Neupulse: Innovative Wearable Device for Tourettes Syndrome Relief
Neupulse, the trading name for Neurotherapeutics Ltd., a health tech company based in Nottingham, UK, recently secured $3.2M in Seed funding to further develop its innovative wearable device for individuals with Tourettes Syndrome. The funding round was led by Eos Advisory, with participation from a group of US-based investors. The company, spearheaded by CEO Paul Cable, aims to bring a non-drug treatment solution to market that can effectively reduce tics and the urge to tic in patients with TS and other tic disorders. The wearable device works by providing gentle stimulation to the median nerve in the wrist, leveraging brain imaging and stimulation techniques to better understand the neural processes associated with tics.
Paul Cable emphasized the company's commitment to improving the quality of life for individuals affected by Tourettes Syndrome, highlighting the debilitating nature of the condition and the significant impact it can have on daily life.
Neupulse's goal is to offer a user-friendly alternative to existing treatments that typically rely on medication and cognitive behavior therapy. By utilizing cutting-edge technology and focusing on neuroplasticity, the company hopes to provide a transformative solution that can benefit the TS community on a global scale. The ultimate vision for Neupulse is to make their innovative device widely accessible in the years to come, offering relief and support to those in need.
Originally established as a spinout from the University of Nottingham in 2021, Neurotherapeutics has made significant strides in the health tech sector with its pioneering approach to treating Tourettes Syndrome. Led by a team of dedicated professionals, including Paul Cable, the company is at the forefront of developing novel solutions that address the underlying neural mechanisms of tics and premonitory urges. Through continuous research and development, Neupulse aims to revolutionize the treatment landscape for TS patients, offering a promising alternative that prioritizes safety, efficacy, and ease of use.
Click here for a full list of 6,908+ startup investors in the UK